- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2016–2021 · research · R01
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
(PQ5) Investigation of intertumoral and intratumoral heterogeneity of mitochondrial apoptotic sensitivity
Anthony G Letai · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research
Advancing Health, Religion, and Spirituality Research from Public Health to End of Life
Tracy Balboni;Tyler Vanderweele · Dana-Farber Cancer Institute · funded by John Templeton Foundation
2016–2018 · career development · K99
Intratumor heterogeneity and therapeutic resistance
Michalina Janiszewska · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
Kenneth C. Anderson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2030 · research · R35
The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations
William G. Kaelin · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R21
Novel Mouse Models to define Genetic Drivers of Aggressive Prostate Cancer
Leigh Ellis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · career development · K99
Roles of tumor-derived PTHrP in skeletal muscle atrophy and cancer cachexia
Serkan Kir · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2026 · research · R01
Conformational Landscape of the HIV-1 Envelope Glycoproteins
Joseph G Sodroski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2027 · research · R01
Axonal transport and chemotherapy induced peripheral neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2020 · award
Epigenetic drivers and dependencies of heterogeneous cellular states
Bradley Bernstein · Dana-Farber Cancer Institute · funded by American Cancer Society
2016–2022 · research · R01
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · award
Targeting RhoA G17V-mediated neoplasia in Peripheral T-cell Lymphomas
Samuel Ng · Dana-Farber Cancer Institute · funded by American Cancer Society
2016–2021 · research · R01
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · research · R01
Identifying causal variants and genes underlying breast cancer risk loci
Matthew L Freedman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K07
Video Informed Consent Tools to Improve Care for Patients With Advanced Pancreatic Cancer
Andrea C Enzinger · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · fellowship · F31
Dissecting the Mitochondrial Translocation Mechanism of Anti-Apoptotic BCL-w
Edward Paul Harvey · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · career development · K07
Material Hardship as a Targetable Measure of Poverty in Pediatric Cancer
Kira O. Bona · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · research · R01
Computational Methods for Genome-Wide CRISPR Screens
Xiaole Shirley Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016 · grant · Lung Cancer Research Foundation Annual Grant Program
2016 – Lung Cancer Research Foundation Annual Grant Program – Dana-Farber Cancer Institute – Matthew Oser, MD, PhD
Matthew Oser · Dana-Farber Cancer Institute · funded by Lung Cancer Research Foundation
2016–2017 · career development · K08
Chemotherapy resistance induced by SETD2 loss in leukemia
Brenton G Mar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2030 · research · R35
Integrating targeted therapy and immunotherapy to break through cancer
Jean Zhao · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · research · R01
Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
Kenneth C. Anderson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · research · R35
Integrating Transforming Approaches to Identify and Target New Vulnerabilities in Cancer
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2017 · grant · PRCRP
The Function of RHOA Mutations in the Development of Diffuse Gastric Cancer
Haisheng Zhang · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2016–2021 · career development · K08
Determining the Role of BCOR Mutations in Myeloid Malignancies
Robert Coleman Lindsley · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · research · R01
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
Rani E. George · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K07
Material Hardship as a Targetable Measure of Poverty in Pediatric Cancer
Kira O. Bona · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Targeting Immunogenicity to the MPER Hinge and C-helix for BNAb Elicitation
Ellis L Reinherz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
Alexander Spektor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2018 · research · R03
CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors
Christopher John Recklitis · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2022 · research · R01
(PQ1) Genomic characterization of mesenchymal stromal cells in Monoclonal Gammopathy of Undermined Significance (MGUS)
Irene M. Ghobrial · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · fellowship · F31
Dissecting the Mitochondrial Translocation Mechanism of Anti-Apoptotic BCL-w
Edward Paul Harvey · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2023 · career development · K00
The role of CMTR2 in Lung Cancer
Alena Yermalovich · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · program · P01
Comprehensive dissection of the CLL genome and phenome to improve patient outcomes
Catherine Ju-Ying Wu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2019 · grant · PRCRP
Directly Conjugated Single-Domain VHHs Targeting MHC Class II Prime T-Cell Responses Against Pancreatic Cancer Neoantigens
Stephanie Dougan · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2016–2021 · research · R01
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2016–2021 · career development · K08
Determining the Role of BCOR Mutations in Myeloid Malignancies
Robert Coleman Lindsley · Dana-Farber Cancer Institute · funded by National Institutes of Health
